Actively Recruiting

Phase 2
Age: 18Years +
MALE
NCT03933670

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Led by University of California, San Francisco · Updated on 2026-02-18

60

Participants Needed

1

Research Sites

519 weeks

Total Duration

On this page

Sponsors

U

University of California, San Francisco

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.

CONDITIONS

Official Title

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Biopsy-proven adenocarcinoma of the prostate with low to intermediate risk by UCSF-CAPRA scoring at study entry
  • Planning to enroll or currently on active surveillance (Part 1)
  • Currently enrolled on active surveillance with planned fusion biopsy within 12 weeks following baseline HP C-13 pyruvate/mpMRI (Part 2)
  • Able and willing to comply with study procedures and provide signed informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Absolute neutrophil count (ANC) at least 1000 cells/microliter
  • Hemoglobin at least 9.0 gm/deciliter
  • Platelets at least 75,000 cells/microliter
  • Estimated creatinine clearance at least 50 mL/min by Cockcroft Gault equation
  • Total bilirubin less than or equal to 1.5 times upper limit of normal (ULN) or up to 3 times ULN if Gilbert's syndrome
  • Aspartate aminotransferase (AST) less than or equal to 1.5 times ULN
  • Alanine aminotransferase (ALT) less than or equal to 1.5 times ULN
Not Eligible

You will not qualify if you...

  • No evidence of prostate cancer on most recent prostate biopsy before study entry
  • Current or prior androgen deprivation therapy including luteinizing hormone-releasing hormone analogue or oral anti-androgen therapy (5-alpha reductase inhibitors allowed if stopped 28 days before baseline MRI)
  • Prior radiation treatment of the prostate
  • Prostate biopsy within 14 days before baseline HP C-13 pyruvate MRI
  • Poorly controlled hypertension with blood pressure over 160 mm Hg systolic or over 100 mm Hg diastolic at study entry
  • Congestive heart failure with New York Heart Association status 2 or higher

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

Loading map...

Research Team

L

Louise Magat

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here